American Century Companies Inc Xencor Inc Transaction History

American Century Companies Inc

$168 Billion
Q4 2024

A detailed history of American Century Companies Inc transactions in Xencor Inc stock. As of the latest transaction made, American Century Companies Inc holds 114,231 shares of XNCR stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

114,231

Previous 102,835 11.08%

Holding current value

$1.8 Million

Previous $2.07 Million 26.93%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$19.43 - $26.84 $221,424 - $305,868	11,396 Added 11.08%	114,231 $2.63 Million
Q3 2024 Nov 12, 2024	BUY	$15.7 - $21.65 $117,122 - $161,509	7,460 Added 7.82%	102,835 $2.07 Million
Q2 2024 Aug 07, 2024	BUY	$18.21 - $24.5 $220,031 - $296,033	12,083 Added 14.51%	95,375 $1.81 Million
Q1 2024 May 14, 2024	BUY	$18.65 - $26.52 $391,687 - $556,973	21,002 Added 33.72%	83,292 $1.84 Million
Q4 2023 Feb 13, 2024	BUY	$16.53 - $21.42 $1.03 Million - $1.33 Million	62,290 New	62,290 $1.32 Million
Q3 2023 Nov 13, 2023	BUY	$20.08 - $25.39 $203,289 - $257,048	10,124 Added 28.6%	45,518 $917,000
Q2 2023 Aug 14, 2023	SELL	$24.77 - $29.9 $198,903 - $240,097	-8,030 Reduced 18.49%	35,394 $883,000
Q1 2023 May 11, 2023	BUY	$25.95 - $36.95 $234,925 - $334,508	9,053 Added 26.34%	43,424 $1.21 Million
Q4 2022 Feb 13, 2023	BUY	$24.79 - $30.86 $588,167 - $732,184	23,726 Added 222.88%	34,371 $895,000
Q3 2022 Nov 14, 2022	BUY	$24.62 - $32.44 $262,079 - $345,323	10,645 New	10,645 $277,000
Q1 2022 May 11, 2022	SELL	$26.68 - $41.63 $133,533 - $208,358	-5,005 Closed	0 $0
Q4 2021 Feb 07, 2022	BUY	$33.67 - $43.44 $168,518 - $217,417	5,005 New	5,005 $201,000

Others Institutions Holding XNCR

# of Institutions

199

Shares Held

73.7M

Call Options Held

1.7K

Put Options Held

4.2K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $940M
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.

Account

American Century Companies Inc Xencor Inc Transaction History